New antibody drug aims to unleash immune cells on Hard-to-Treat cancers
Disease control
Not yet recruiting
This early-phase study tests a new drug called NPX372 in people with advanced solid tumors that have not responded to standard treatments. NPX372 is designed to attach to both cancer cells and immune cells, helping the immune system attack the cancer. The main goals are to check …
Phase: PHASE1 • Sponsor: NextPoint Therapeutics, Inc. • Aim: Disease control
Last updated May 07, 2026 18:41 UTC